CVKDCadrenal Therapeutics, Inc.

Nasdaq www.cadrenal.com


$ 0.47 $ -0.03 (-5.23 %)    

Friday, 10-May-2024 15:52:29 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 0.46
$ 0.48
$ 0.00 x 0
$ 0.00 x 0
$ 0.47 - $ 0.48
$ 0.36 - $ 3.14
114,674
na
7.36M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cadrenal-therapeutics-q1-eps-010-misses-007-estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-reiterates-buy-on-cadrenal-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...

 cadrenal-therapeutics-receives-fda-orphan-drug-designation-for-tecarfarin-for-prevention-of-thromboembolism-and-thrombosis-in-patients-with-lvads-rvads-biventricular-assist-devices-and-total-artificial-hearts

FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for...

 hc-wainwright--co-reiterates-buy-on-cadrenal-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...

 cadrenal-therapeutics-announces-q4-2023-operating-expenses-totaled-116m-cash-used-in-operating-activities-totaled-694000-during-q4-2023-as-of-december-31-2023-cash-balances-were-85m

Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reve...

 why-compass-minerals-international-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

 cadrenal-therapeutics-appoints-jeff-cole-as-chief-operating-officer-in-advance-of-tecarfarin-phase-3-pivotal-trial

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA...

 why-4d-molecular-therapeutics-shares-are-trading-higher-by-20-here-are-20-stocks-moving-premarket

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim da...

 why-skechers-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarte...

 why-tellurian-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hi...

 why-netflix-shares-are-trading-higher-by-10-here-are-20-stocks-moving-premarket

Shares of Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-e...

 why-keycorp-shares-are-trading-lower-by-over-5-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION